Compare WEN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEN | ABCL |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2000 | 2020 |
| Metric | WEN | ABCL |
|---|---|---|
| Price | $7.35 | $5.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 22 | 5 |
| Target Price | ★ $8.84 | $8.40 |
| AVG Volume (30 Days) | ★ 9.9M | 5.2M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $2,176,891,000.00 | $75,128,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | $0.94 | $21.85 |
| P/E Ratio | $61.13 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $6.07 | $2.75 |
| 52 Week High | $10.84 | $8.44 |
| Indicator | WEN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 43.22 |
| Support Level | $6.79 | $5.17 |
| Resistance Level | $8.26 | $5.63 |
| Average True Range (ATR) | 0.31 | 0.43 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 35.55 | 30.26 |
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.